NASDAQ:BLCM Bellicum Pharmaceuticals (BLCM) News Today $0.30 -0.32 (-51.61%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$0.15▼$0.5350-Day Range$0.26▼$0.9652-Week Range$0.15▼$1.55Volume234,724 shsAverage Volume5.97 million shsMarket Capitalization$2.85 millionP/E RatioN/ADividend YieldN/APrice TargetN/A HeadlinesProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Get Bellicum Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BLCM and its competitors with MarketBeat's FREE daily newsletter. Email Address BLCM Media Mentions By Week BLCM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BLCM News Sentiment▼0.000.55▲Average Medical News Sentiment BLCM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BLCM Articles This Week▼21▲BLCM Articles Average Week All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineBellicum Pharmaceuticals (NASDAQ: BLCM)fool.com - June 3 at 2:07 PMBellicum Pharmaceuticals (NASDAQ:BLCM) Now Covered by Analysts at StockNews.comamericanbankingnews.com - June 2 at 5:06 AMBellicum Pharmaceuticals (NASDAQ:BLCM) Coverage Initiated at StockNews.comamericanbankingnews.com - May 26 at 4:16 AMBellicum Pharmaceuticals (NASDAQ:BLCM) Earns Sell Rating from Analysts at StockNews.comamericanbankingnews.com - May 19 at 4:50 AMBellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Short Interest Updateamericanbankingnews.com - May 12 at 6:34 AMmarketbeat.com - May 8 at 12:13 PMmarketbeat.com - May 8 at 12:13 PMWhy Is Bellicum Pharmaceuticals (BLCM) Stock Up 75% Today?investorplace.com - May 8 at 9:08 AMBellicum Pharmaceuticals (NASDAQ:BLCM) Now Covered by StockNews.comamericanbankingnews.com - May 1 at 5:40 AMStockNews.com Initiates Coverage on Bellicum Pharmaceuticals (NASDAQ:BLCM)americanbankingnews.com - April 24 at 1:34 AMWhy Digital Brands Group Shares Are Trading Lower By Over 15%; Here Are 20 Stocks Moving Premarketmsn.com - April 18 at 8:18 PMShort Volatility Alert: Bellicum Pharmabenzinga.com - April 18 at 10:17 AMBellicum Pharmaceuticals (NASDAQ:BLCM) Coverage Initiated by Analysts at StockNews.comamericanbankingnews.com - April 15 at 6:45 AMBellicum Pharmaceuticals (NASDAQ:BLCM) Receives New Coverage from Analysts at StockNews.comamericanbankingnews.com - April 7 at 6:44 AMBellicum Pharmaceuticals (BLCM) Scheduled to Post Quarterly Earnings on Wednesdayamericanbankingnews.com - March 21 at 9:06 AMBellicum Pharmaceuticals (BLCM) Set to Announce Quarterly Earnings on Wednesdayamericanbankingnews.com - March 21 at 8:15 AMBLCM Plummets on Stopping Trials of BPX-601 and BPX-603msn.com - March 15 at 3:54 PMWhy Bellicum Pharmaceuticals (BLCM) Stock Is Down 48%msn.com - March 15 at 3:54 PMBellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic Alternativesfinance.yahoo.com - March 14 at 6:54 PMmarketbeat.com - March 14 at 4:26 PMWhy Bellicum Pharmaceuticals Stock Is Plunging Todayfinance.yahoo.com - February 24 at 1:47 AMBellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO GU Cancers Symposiumfinance.yahoo.com - February 16 at 7:54 AMCORRECTION -- Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)finance.yahoo.com - January 31 at 8:11 PMBellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers Symposiumfinance.yahoo.com - January 19 at 12:39 PMmarketbeat.com - January 6 at 2:59 PMBellicum Pharmaceuticals, Inc.: Bellicum Reports Third Quarter 2022 Financial Results and Provides Operational Updatefinanznachrichten.de - November 13 at 5:28 PMBellicum Reports Third Quarter 2022 Financial Results and Provides Operational Updatefinance.yahoo.com - November 10 at 8:16 PMBellicum Pharmaceuticals to Participate in the 2022 Cell & Gene Meeting on the Mesafinance.yahoo.com - October 4 at 10:57 AMBLCM Bellicum Pharmaceuticals, Inc.seekingalpha.com - September 15 at 7:27 PMBellicum Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conferencefinance.yahoo.com - September 1 at 9:53 AMBellicum Pharmaceuticals (BLCM) Could Find Support Soon, Here's Why You Should Buy the Stock Nowfinance.yahoo.com - August 25 at 12:15 PMIs Immunocore (IMCR) Stock Outpacing Its Medical Peers This Year?finance.yahoo.com - August 18 at 1:03 PMBellicum Reports Second Quarter 2022 Financial Results and Provides Operational Updatefinance.yahoo.com - August 11 at 7:18 PMBellicum Pharmaceuticals GAAP EPS of -$0.25 beats by $0.42seekingalpha.com - May 13 at 2:26 AMBellicum Reports First Quarter 2022 Financial Results and Provides Operational Updatefinance.yahoo.com - May 13 at 2:26 AMBellicum Reports Fourth Quarter 2021 Financial Results and Provides Operational Updatefinance.yahoo.com - March 24 at 4:52 PMLadenburg Thalmann Initiates Coverage On Bellicum Pharmaceuticals with Buy Rating, Announces Price Target of $5benzinga.com - February 16 at 12:22 PMBellicum Pharmaceuticals Inc. BLCMstockhouse.com - January 28 at 9:07 PMBellicum Pharmaceuticals to Participate in the B. Riley Securities 2022 Virtual Oncology Conferencefinance.yahoo.com - January 26 at 6:08 PMBellicum Regains Compliance with Nasdaq Continued Listing Requirementsfinance.yahoo.com - December 13 at 6:11 PMSumitovant Biopharma Highlights Significant Clinical, Regulatory and Commercial Achievements Across its Portfolio of Companies in the Second Quarter of FY2021finance.yahoo.com - December 10 at 1:11 PMBellicum Secures $35M Via Equity Funding, Posts Interim Data From Early GoCAR-T Cancer Studiesmsn.com - December 7 at 4:48 AMBellicum Reports Positive Interim Data From Phase 1/2 GoCAR-T Trials - Quick Factsmarkets.businessinsider.com - December 6 at 12:45 PMBellicum Announces Positive Interim Data from Phase 1/2 GoCAR-T® Studies, Secures $35 Million Private Placement Equity Financing Priced at Marketfinance.yahoo.com - December 6 at 7:44 AMK2 BioLabs hiring, expanding contract research offerings for biotech, pharma startupsbizjournals.com - December 2 at 6:56 PMBellicum Reports Third Quarter 2021 Financial Results and Provides Operational Updatefinance.yahoo.com - November 4 at 7:52 PMBellicum Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment ...apnews.com - September 3 at 3:46 PMBellicum Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conferencefinance.yahoo.com - September 3 at 3:46 PMBellicum and MD Anderson Announce Additional License Agreement for Use of CaspaCIDe® Safety Switchfinance.yahoo.com - September 1 at 6:25 PMBellicum Pharmaceuticals: Q2 Earnings Snapshotsfgate.com - August 12 at 9:49 PM Get Bellicum Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BLCM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Exicure News Today Sonnet BioTherapeutics News Today Petros Pharmaceuticals News Today Tenax Therapeutics News Today Adamis Pharmaceuticals News Today Aytu BioPharma News Today RedHill Biopharma News Today NeuBase Therapeutics News Today Galmed Pharmaceuticals News Today AcelRx Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:BLCM) was last updated on 6/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bellicum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.